Clinical practice guideline for #NephJC?
What do people think about this? Is this appropriate for journal club or is this akin to doing a review article?
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Why does the CKD screening matters? Because of this: http://t.co/HKuUTJgZvR @NephJC #nephJC
— Xavier F. Vela (@xaviervel) May 6, 2014
Though not a tradition subject for journal club, it seems that clinical practice guidelines have an important role in today’s practice (1/2)
— Joel Topf (@kidney_boy) May 5, 2014
I propose the new hyponatremia guidelines for #NephJC http://t.co/hNGxibmNfy (2/2)
— Joel Topf (@kidney_boy) May 5, 2014
What do people think about this? Is this appropriate for journal club or is this akin to doing a review article?
Chronic kidney disease blast Central America: http://t.co/7Yxkf8uMfb #renalweek #kidneyweek #NephJC pic.twitter.com/4XyXCbkzma
— Xavier F. Vela (@xaviervel) May 1, 2014
Latest hope for DN: endothelin antagonists http://t.co/64hQ0rs5xX one for #NephJC? @NephJC @kidney_boy
— Paul Phelan (@paulphel) April 23, 2014
http://t.co/siLrMR1v7i Time for routine kidney biopsy in all patients (not just the risk ones) with suspected GN? Paper for #NephJC ?
— ChristosArgyropoulos (@ChristosArgyrop) April 23, 2014
Prenatal risk factors for childhood CKD in JASN -- a possible peg article for #NephJC? http://t.co/t7hmG91XXS
— NatureRevNephrology (@NatRevNeph) April 25, 2014
Atrasentan lowers residual albuminuria T2DM, but ... "manageable" fluid-overload. #NephJC #CJASN http://t.co/G5C6FT5PSu
— Ernesto LopezAlmaraz (@kidney_doctor) April 29, 2014